Skip to main content
OpenTrials

Clinical trial condition

Skin Diseases

Explore clinical trials studying Skin Diseases. Study availability and eligibility vary by location and protocol.

22,973 public trials 3,715 recruiting studies
Refine in advanced search Browse all conditions

Skin Diseases trial results

Terminated

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

NCT03820947

Conditions
Cardiovascular Diseases, Leg Ulcer, Skin Diseases, +6 more
Locations
  • Yavapai Regional Medical Center Prescott Valley, Arizona, United States
  • PIMA Heart and Vascular Tucson, Arizona, United States
  • Valley Vascular Surgical Associates Fresno, California, United States
  • Vascular Care Connecticut Darien, Connecticut, United States
View all 32 locations
View Trial Details
Terminated

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT07214662

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations
  • START - Midwest - EDOS Grand Rapids, Michigan, United States
  • START - San Antonio - EDOS San Antonio, Texas, United States
  • National Taiwan University Hospital Taipei, Taipei City, Taiwan
  • National Cheng Kung University Hospital Tainan, Taiwan
View Trial Details
Terminated

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +6 more
Locations
  • The START Center for Cancer Research Los Angeles, California, United States
  • The START Center for Cancer Research Lake Success, New York, United States
  • NEXT Oncology Austin, Texas, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Terminated

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT05827614

Conditions
Anogenital Cancer, Breast Diseases, Breast Neoplasms, +38 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • Sarcoma Oncology Santa Monica, California, United States
  • HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists Lake Mary, Florida, United States
View all 16 locations
View Trial Details
Terminated

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • Moores Cancer Center ( Site 0116) La Jolla, California, United States
  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131) Los Angeles, California, United States
  • California Pacific Medical Center - Pacific Campus ( Site 0111) San Francisco, California, United States
View all 205 locations
View Trial Details
Terminated

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185

Conditions
Angioedema, Angioedemas, Hereditary, C1 Esterase Inhibitor Deficiency, +23 more
Locations
  • Study site Birmingham, Alabama, United States
  • Study site Paradise Valley, Arizona, United States
  • Study site St Louis, Missouri, United States
  • Study Site Vienna, Austria
View all 19 locations
View Trial Details

Related conditions